Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder

NCT07218354 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

622

Enrollment

FED

Sponsor class

Conditions

Alcohol Use Disorder

Interventions

DRUG: Semaglutide
DRUG: Placebo

Sponsor

VA Office of Research and Development